| Thiennu Huy Vu, MD | |
|
2330 Post Street #420, San Francisco, CA 94115 | |
| (415) 885-7755 | |
| (415) 885-3852 |
| Full Name | Thiennu Huy Vu |
|---|---|
| Gender | Female |
| Speciality | Pulmonary Disease |
| Experience | 33 Years |
| Location | 2330 Post Street #420, San Francisco, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275549438 | NPI | - | NPPES |
| 00G756650 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | G75665 (California) | Primary |
| 207R00000X | Internal Medicine | G75665 (California) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ucsf Medical Center | San francisco, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Regents Of The University Of California | 4284547274 | 563 |
News Archive
University of Manchester researchers have used a new technique to recondition poorly functioning lungs and remove donor white blood cells in an attempt to increase the number of lungs available for transplant, and at the same time reduce the risk of acute rejection.
Scientists at the University of Liverpool have found how two molecules fight in the blood to control the spread of cancer cells.
HemaQuest Pharmaceuticals, a clinical stage biotechnology company developing small molecule therapeutics for sickle cell disease, beta thalassemia and EBV-related cancers, announced today the closing of an additional $4M to its Series B financing by new investor, Latterell Venture Partners. This investment brings the total Series B financing to $16M.
Neoprobe Corporation, a diversified developer of innovative oncology and surgical diagnostic and treatment products, today announced that it recently met with the United States Food and Drug Administration to review the clinical trial results of a Phase 3 investigational new drug, Lymphoseek®.
Politico reports that despite its health reform efforts, Massachusetts is having trouble getting the federal government to issue a waiver for Medicaid programs. The Wall Street Journal reports on the growing needs in New York.
› Verified 4 days ago
| Entity Name | Regents Of The University Of California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881763597 PECOS PAC ID: 4284547274 Enrollment ID: O20031106000389 |
News Archive
University of Manchester researchers have used a new technique to recondition poorly functioning lungs and remove donor white blood cells in an attempt to increase the number of lungs available for transplant, and at the same time reduce the risk of acute rejection.
Scientists at the University of Liverpool have found how two molecules fight in the blood to control the spread of cancer cells.
HemaQuest Pharmaceuticals, a clinical stage biotechnology company developing small molecule therapeutics for sickle cell disease, beta thalassemia and EBV-related cancers, announced today the closing of an additional $4M to its Series B financing by new investor, Latterell Venture Partners. This investment brings the total Series B financing to $16M.
Neoprobe Corporation, a diversified developer of innovative oncology and surgical diagnostic and treatment products, today announced that it recently met with the United States Food and Drug Administration to review the clinical trial results of a Phase 3 investigational new drug, Lymphoseek®.
Politico reports that despite its health reform efforts, Massachusetts is having trouble getting the federal government to issue a waiver for Medicaid programs. The Wall Street Journal reports on the growing needs in New York.
› Verified 4 days ago
| Entity Name | University Of California San Francisco |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861578973 PECOS PAC ID: 4486567229 Enrollment ID: O20031212000897 |
News Archive
University of Manchester researchers have used a new technique to recondition poorly functioning lungs and remove donor white blood cells in an attempt to increase the number of lungs available for transplant, and at the same time reduce the risk of acute rejection.
Scientists at the University of Liverpool have found how two molecules fight in the blood to control the spread of cancer cells.
HemaQuest Pharmaceuticals, a clinical stage biotechnology company developing small molecule therapeutics for sickle cell disease, beta thalassemia and EBV-related cancers, announced today the closing of an additional $4M to its Series B financing by new investor, Latterell Venture Partners. This investment brings the total Series B financing to $16M.
Neoprobe Corporation, a diversified developer of innovative oncology and surgical diagnostic and treatment products, today announced that it recently met with the United States Food and Drug Administration to review the clinical trial results of a Phase 3 investigational new drug, Lymphoseek®.
Politico reports that despite its health reform efforts, Massachusetts is having trouble getting the federal government to issue a waiver for Medicaid programs. The Wall Street Journal reports on the growing needs in New York.
› Verified 4 days ago
| Entity Name | Ucsf Medical Group Business Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477624104 PECOS PAC ID: 3779497870 Enrollment ID: O20040622001513 |
News Archive
University of Manchester researchers have used a new technique to recondition poorly functioning lungs and remove donor white blood cells in an attempt to increase the number of lungs available for transplant, and at the same time reduce the risk of acute rejection.
Scientists at the University of Liverpool have found how two molecules fight in the blood to control the spread of cancer cells.
HemaQuest Pharmaceuticals, a clinical stage biotechnology company developing small molecule therapeutics for sickle cell disease, beta thalassemia and EBV-related cancers, announced today the closing of an additional $4M to its Series B financing by new investor, Latterell Venture Partners. This investment brings the total Series B financing to $16M.
Neoprobe Corporation, a diversified developer of innovative oncology and surgical diagnostic and treatment products, today announced that it recently met with the United States Food and Drug Administration to review the clinical trial results of a Phase 3 investigational new drug, Lymphoseek®.
Politico reports that despite its health reform efforts, Massachusetts is having trouble getting the federal government to issue a waiver for Medicaid programs. The Wall Street Journal reports on the growing needs in New York.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thiennu Huy Vu, MD Po Box 7464, San Francisco, CA 94120-7464 Ph: (415) 206-3103 | Thiennu Huy Vu, MD 2330 Post Street #420, San Francisco, CA 94115 Ph: (415) 885-7755 |
News Archive
University of Manchester researchers have used a new technique to recondition poorly functioning lungs and remove donor white blood cells in an attempt to increase the number of lungs available for transplant, and at the same time reduce the risk of acute rejection.
Scientists at the University of Liverpool have found how two molecules fight in the blood to control the spread of cancer cells.
HemaQuest Pharmaceuticals, a clinical stage biotechnology company developing small molecule therapeutics for sickle cell disease, beta thalassemia and EBV-related cancers, announced today the closing of an additional $4M to its Series B financing by new investor, Latterell Venture Partners. This investment brings the total Series B financing to $16M.
Neoprobe Corporation, a diversified developer of innovative oncology and surgical diagnostic and treatment products, today announced that it recently met with the United States Food and Drug Administration to review the clinical trial results of a Phase 3 investigational new drug, Lymphoseek®.
Politico reports that despite its health reform efforts, Massachusetts is having trouble getting the federal government to issue a waiver for Medicaid programs. The Wall Street Journal reports on the growing needs in New York.
› Verified 4 days ago
Dr. Pratyusha Kishore Narra, MBBS Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3490 California St, San Francisco, CA 94118 Phone: 415-514-6200 Fax: 415-514-6410 | |
Dr. Chelsea Joy Thomsen, M.D., M.S.P.H Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2 W Portal Ave, San Francisco, CA 94127 Phone: 415-291-0480 | |
Christine Soran, Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 1001 Potrero Ave, Bldg 10, 3rd Floor, Ward 13, Ucsf Division Of General Internal Medicine Sfgh, San Francisco, CA 94110 Phone: 415-206-5164 Fax: 415-206-5586 | |
Stephen Norris Cohen, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 40 Ventura Ave, San Francisco, CA 94116 Phone: 415-681-2171 Fax: 415-681-2171 | |
Mauricio Jalife Bucay, M.D Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 505 Parnassus Ave, San Francisco, CA 94143 Phone: 415-750-4994 Fax: 415-750-8156 | |
Dr. Adriana A.t. Martin, M.D., PH.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 505 Parnassus Ave, San Francisco, CA 94143 Phone: 415-514-7288 | |
Dr. Alexandra Cristina Villasante Fricke, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 655 Montgomery St Ste 810, San Francisco, CA 94111 Phone: 844-847-8216 Fax: 415-520-9150 |